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Should local treatment of breast ductal carcinoma in situ be the same  
as the treatment of early invasive breast cancer
Sylwia Grodecka-Gazdecka
Heterogenicity of breast ductal carcinoma in situ gives rise to opposing proposals concerning its treatment — ranging 
from attempts to recommend the watch and wait strategy in low risk forms ending with the currently binding stan-
dards of treatment of DCIS in the way identical as early invasive cancer in the high risk. Arguments for the treatment 
of ductal carcinoma in situ in the same way as patients with early invasive cancer have been presented. These argu-
ments comprise: unknown natural history of untreated DCIS, high risk of undervaluation of the invasive component 
in the core-needle biopsy, the increase of recurrence risk with the progress of time, lack of verified separators of the 
groups with the risk of adverse course of the disease, the results of the clinical studies confirming the justification of 
combined local treatment and the proof that the clinical course of DCIS is the same as early invasive breast cancer, 
and, first and foremost, the fact that there are no clinical studies which could justify a limitation of the treatment scope.
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Breast ductal carcinoma in situ (DCIS) is characterised 
with a malignant transformation of the epithelium of the 
ducts, which is limited to the epithelia and myoepithelial 
layers without crossing the basal cell membrane. This type 
of cancer is regarded as a transitional stage between the 
normal breast tissue and invasive cancer. It is characterised 
with a significant diversity of the morphological, immuno-
chemical, molecular and clinical picture [1]. Depending on 
the tissue architecture, DCIS can be defined as solid, cribri-
form, papillary and micropapillary; whilst depending on 
the malignancy grade, as: poorly-, moderately- and highly 
differentiated and — depending on the presence of the 
comedo type necrosis — as comedo type carcinoma (with 
a more aggressive clinical course) and non-comedo type 
carcinoma. Intraductal spread of the disease in connection 
with an irregular routing of the ducts and difficulties in ma-
croscopic evaluation of the scope of the lesions illustrates 
well the deceptive character of the disease and the widely 
understood heterogenicity of the DICS requires some si-
gnificant evaluation of the therapeutic management [2]. 
The risk of development of an invasive form of cancer, which 
— depending on the subtype of DCIS — is 20–30% within 
10 years and is 15 times greater than the average risk of 
breast cancer morbidity in the general population [3] of 
key importance for the choice of the scope of treatment.
The scale of the problem can be illustrated with the fact 
that since the 1970s there has been a continued increase in 
diagnoses of ductal carcinoma in situ due to the popularisa-
tion of screening examinations and more advanced diagno-
stic techniques. Currently DCIS makes up about 20–25% of 
breast cancers in the Western countries and in Poland 7–10% 
of new diagnoses per year [4]. In spite of the increasing 
number of DCIS diagnoses and early invasive cancers, the 
number of diagnoses of advanced breast cancer have not 
dropped, which remains a paradox [5]. 
Diagnosis of ductal breast carcinoma in situ is made in 
90% of cases during a screening mammography, whilst, in 
a clinical examination such diagnosis is made much more 
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rarely, usually only when a tumour in the breast or an exu-
dation from a papilla is found. DCIS comprises a vast range 
of symptoms, from some slight low-risk lesions to eventually 
the involvement of extensive breast areas with lesions of 
high malignancy potential. The most frequent symptom 
of the disease consists in lesions, visible in mammogra-
phy as accumulations of malignant micro-calcifications, 
which can be uni- or bilateral, frequently multifocal. The 
MRI mammography, useful in particular for the evaluation 
of the multifocality of neoplastic lesions and a more accu-
rate estimation of the tumour size, is more sensitive than 
classical mammography. A microscopic diagnosis is usually 
made from the specimen collected in a mammotomy biopsy 
or — less frequently — in the surgical specimen, in which 
DICS may occur independently or co-exist with an invasive 
carcinoma.
The primary objective in the DCIS treatment is to reduce 
the number of recurrences and to decrease the number of 
recurrences with an invasive component. The determination 
of the groups with the risk of an adverse course of the di-
sease is of essential importance for the choice of optimum 
therapeutic management. The DCIS heterogenicity thus 
gives rise to opposing proposals concerning its treatment — 
from attempts to recommend the watch and wait strategy 
in low risk forms to currently binding standards of treatment 
of DCIS in the same way as early invasive cancer in the high 
risk group [6]. 
The scope of treatment of DCIS ranges from the re-
section of the neoplastic lesion, through an excision with 
an adjuvant hormonotherapy, excision with the sentinel 
node biopsy and adjuvant radiotherapy, excision with the 
sentinel node biopsy and adjuvant radiotherapy with hor-
monotherapy, simple mastectomy, simple mastectomy with 
the sentinel node biopsy, subcutaneous mastectomy with 
the sentinel node biopsy and immediate reconstruction to 
end with the subcutaneous mastectomy with the sentinel 
node biopsy and immediate reconstruction and adjuvant 
hormonotherapy. The choice of the optimum scope of loco-
regional treatment is usually assisted with the assessment 
of the prognostic value of the Van Nuys Prognostic Index 
(VNPI), worked out in 2002 or VNPI/SCI, corrected in 2009 
[7]. Amongst the tools recommended for a more specific 
prediction of the course of the disease, are also genetic tests, 
including Oncotype DX and the examination of the BRCA1 
and BRCA2 gene mutation [8, 9]. 
The most popular locoregional management is organ 
sparing treatment, consisting of the resection of the neopla-
stic lesion with an adjuvant radiotherapy. The indications for 
the sentinel node biopsy are limited to patients with a high 
risk of the presence of a malignant component, (large areas 
of malignant calcifications, location in the tail of Spence, 
planned mastectomy) [10]. In spite of the predominance 
of breast sparing treatment, the published data points to 
significant differentiation of treatment choices resulting 
from the attitudes of the patients and the experience of 
the therapeutic team [11, 12]. In the USA, after the period 
of a decrease in the number of mastectomies in 1998–2004 
(from 36 to 28%), since 2011 a further growth in the number 
of breast amputations, following the diagnose of DCIS has 
been observed, correlating additionally with the increase 
of the contralateral breast amputation. This concerns mo-
stly younger patients, BRCA1 gene carriers, in particular, in 
families with a family history burdened with ovarian cancer 
[9]. An additional argument for this option is the reluctance 
for revision surgeries necessary to obtain a cancer-free mar-
gin, chimeric course of the disease in spite of a lack of any 
signs of invasion, the possibility to avoid radiotherapy and 
access to the procedures of immediate breast reconstruction 
[13–15]. This escalation of the scope of surgical treatment is 
one of the mechanisms driving the debate on the necessity 
to look for decision factors, allowing the optimisation of the 
treatment of breast ductal carcinoma in situ.
The basic arguments for the treatment of ductal carcino-
ma in situ in the same way as early invasive cancer comprise:
 — unknown natural history of untreated DCIS [16];
 — high risk of undervaluation of the invasive component 
in the core-needle biopsy [10, 16–18];
 — increase of recurrence risk with the progress of time 
[3, 19–21];
 — lack of verified separators of the groups with the risk of 
adverse course of the disease [1, 2, 20];
 — the results of the clinical studies confirming the justifi-
cation of combined local treatment [22–26];
 — and the proof that the clinical course of DCIS is the same 
as early invasive breast cancer [27, 28];
 — the lack of clinical studies which could justify a limitation 
of the treatment scope [28–30].
Given the fact that a large share of ductal carcinoma 
in situ is diagnosed as a small lesion seen only in a mam-
mography image, and then treated with a mammotomy 
biopsy, a substantial part of DCIS is resected during this 
procedure. Thus, the natural history of untreated DCIS re-
mains unknown [16]. 
According to the published data, in 10 to 50% patients 
with ductal carcinoma in situ diagnosed during a core-ne-
edle or mammotomy biopsy, there is a risk of the undere-
stimation of the co-existence of an invasive component, 
which is illustrated by microscopic evaluation performed 
after the surgical resection of the lesion [2, 10, 17, 18]. In the 
opinion of the authors of this meta-analysis, which compri-
sed 7350 subject with a diagnosis of DCIS established with 
a core-needle biopsy, a consequence of underestimation 
of the risk of the presence of an invasive component was 
the delay of the correct diagnosis and treatment in one out 
of five cases. The presence of invasive cancer was found in 
1738 patients from the analysed group [18]. In the studies 
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in which an invasive component was diagnosed in 40% of 
patients, the following factors were regarded as a risk: the 
presence of tissue mass in the preoperative MRI mammo-
graphy, the involvement of the nipple-areolar complex, 
a large heterogenicity of the lesion and HER2 overexpression 
[10, 17]. The recurrence risk increases with the progress of 
time and, given the unknown natural history of untreated 
DICS, the observations concerning disease recurrence are 
a source of knowledge of DICS biology and the effects on 
the therapy applied. In one-centre retrospective study com-
prising 200 patients, within an 8-year observation period, 
in 25 patients (12.5%) a disease recurrence was diagnosed, 
and the risk factors were the young age, tumour size and 
grade [3]. In a prospective multicentre trial, ECOG-ACRIN 
E5194 with an average observation period of 12.3 years, 
where the minimum cancer-free margin was more than 3 
mm, special attention was paid to the group of patients with 
a potentially low recurrence risk low-grade DCIS. In this gro-
up, comprising 561 patients, also 14.4% of recurrence cases 
were found (vs 24.6% in the high-grade group), including 
7.5% invasive recurrences (vs 13.4% in the high-grade group) 
[19]. In the group of patients with an almost 20-year obse-
rvation period, after the treatment of asymptomatic DCIS, 
found in the mammographic picture, 16.3% of recurrences 
were found, ¾ of which were invasive and the independent 
risk factor was an age below 45 years [24]. 
In spite of the probability of a different course of disease 
depending on the group with a low or high tumour grade, 
there are no verified and well documented risk separators. 
The knowledge of the molecular aspect of DCIS will allow 
for a better understanding of heterogenicity of this type of 
cancer and its significance for the clinical picture of a disease. 
For the time being the studies concentrate on the analysis 
of epigenetic modifications such as DNA methylation and 
the changes within miRNA, which play a significant role in 
genetic disorders. Additionally, the tumour increase and 
invasion are facilitated by a distorted tumour microenviron-
ment, whose fibroblasts and macrophages excrete growth 
factors and angiogenesis stimulating factors [1]. Another 
group of molecular studies concern the relationships of 
the expression of selected biomarkers and the prognoses, 
where the triple-positive DCIS (p16, COX-2, Ki67) is signifi-
cantly related to a higher risk of the occurrence of invasive 
breast cancer [31]. 
In the light of the recent studies whose results may in 
future foster the modification of clinical decisions, it must 
be concluded that the current state of knowledge, providing 
strong evidence justifying the local treatment of breast DCIS 
in the same way as early invasive form of this cancer [22]. 
With regards to the strength of the arguments from clinical 
studies, an identical standpoint is presented in the current 
recommendations of NCCN, AGO, ESMO or recommenda-
tions of the Polish Society of Surgical Oncology, currently 
prepared for publication [32–34]. The arguments for the 
positive answer were provided, among others, by the results 
of the NSABP studies: B-17 and B-24 in their section concer-
ning DCIS. Within more than a 15-year observation period, 
490 recurrences were observed, including 263 (53.7%) in-
vasive cases, which were related to a higher risk of death. 
A significant reduction of recurrences was confirmed in 
the group of patients undergoing adjuvant radiotherapy 
(and also among those treated with tamoxifen). The share 
of contralateral breast cancer, within the period of 15 years 
was 10% in the studied groups, whilst it was reduced to 7.3% 
after the addition of tamoxifen to the therapy. It was proven 
that multiple year prognoses after surgical treatment is very 
good [23]. The recurrence risk factors were the young age of 
the patients and the lack of a tumour free margin [23, 35].
A definition of an adequate margin still remains under 
discussion. What is beyond all doubt, however, is the signi-
ficance of the cancer-free margin as the strongest risk factor 
of local recurrence [36–39]. In accordance with the St. Gallen 
recommendations, a cancer free margin means the lack of 
cells of invasive or pre-invasive cancer in the excision line 
(“no ink on invasive tumour or DCIS”) [40]. In the meta-ana-
lysis of 20 studies, published in August 2016 and concerning 
as many as 7883 patients with a mean observation period 
of 78.3 months, a definite standpoint of three opinion-for-
ming American scientific societies (SSO, ASTRO, ASCO), that 
a standard in the treatment of DCIS is a margin not smaller 
than 2 mm in patients undergoing surgical intervention and 
a radical adjuvant radiotherapy (WBRT) [41]. 
The application of adjuvant radiotherapy in breast 
conserving surgery in the patients with DCIS has a proven 
significance for decreasing the recurrence risk [26]. The 
prospective clinical study, RTOG 9804, proved the benefit 
in adjuvant radiotherapy also in the group of patients with 
good prognoses (low and medium recurrence risk in the 
patients with negative surgical margin). During the mean 
observation period of 7.17 years in the group of patients wi-
thout irradiation, there was 42% cases of disease recurrence, 
whilst the addition of radiotherapy resulted in a reduction 
of the recurrence risk from 6.7% to 0.9% [25]. The analysis of 
data coming from the SEER register (Surveillance, Epidemio-
logy and End Results), concerning the population of 56968 
people treated for DCIS with an average observation period 
of 91 months, confirmed the beneficial effect of adjuvant 
radiotherapy on the overall survival period throughout the 
entire study group, yet this effect was expressed in the stron-
gest way in younger patients, without or with a low content 
of oestrogen receptors in the nuclei of the cancer cells [42]. 
Strong arguments for the treatment of DCIS in the same 
way as early invasive cancer are also presented in the pu-
blications in which the analysis of the data from the SEER 
register concerning 108 196 women with a diagnosis of DCIS 
confirms the fact that the clinical course of the disease in 
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both groups of patients is similar [27, 28]. One of the most 
essential contra-arguments against the reduction of local 
treatment, even in the group defined as low risk DCIS, is 
the lack of results of such randomised clinical studies as 
LORIS in Great Britain, which is a prospective study com-
paring surgical treatment (plus adjuvant radiotherapy or 
hormonotherapy) with an active observation, which was 
supposed to foster better understanding of the natural 
history of untreated DCIS [29]. In 2015 also, the LORD study 
was started (the third phase study EORTC-BCG 1401/BOOG 
2014-04), in which in 1240 patients with a diagnosis of low 
risk DCIS, and with a 10 year follow-up period and active 
observation (watch and wait strategy) will be compared 
with treatment considered so far to be the standard [30]. 
In the light of the presented facts, the authors of this 
publication wish to sustain their standpoint that a local 
treatment of a patient with a ductal carcinoma in situ should 
be the same as the treatment of patients with early invasive 
cancer, as there is strong evidence for the effectiveness of 
the local treatment of DCIS, whilst the abandonment of 
surgical treatment and the treatment combined with ra-
diotherapy remains premature without any data from the 
prospective clinical studies which could confirm the safety 
of such procedure.
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